Variables | Values |
---|---|
Demographic data | |
Age (years) | 62.0 (21.0) |
Male sex (N (%)) | 27 (34.6) |
Variants (N(%)) | |
MPA | 40 (51.3) |
GPA | 21 (26.9) |
EGPA | 17 (21.8) |
AAV-specific indices | |
BVAS | 7.0 (11.0) |
FFS | 1.0 (1.0) |
VDI | 3.0 (2.0) |
SF-36 PCS score | 48.0 (36.2) |
SF-36 MCS score | 57.0 (34.5) |
ANCA positivity (N(%)) | |
MPO-ANCA positivity | 43 (55.1) |
PR3-ANCA positivity | 7 (9.0) |
ANCA negativity | 28 (35.9) |
Clinical manifestations (N(%)) | |
General | 27 (34.6) |
Cutaneous | 9 (11.5) |
Mucous membrane and eye | 5 (6.4) |
Ear, nose, and throat | 36 (46.2) |
Pulmonary | 50 (64.1) |
Cardiovascular | 5 (6.4) |
Abdominal | 0 (0) |
Renal | 39 (50.0) |
Nervous system | 17 (21.8) |
Acute-phase reactants | |
ESR (mm/h) | 37.5 (44.0) |
CRP (mg/L) | 2.6 (14.6) |
IL-16 (pg/mL) | 84.1 (198.7) |